Related Experiment Videos
Effect of athrombogenic therapy, especially high dose therapy of dipyridamole, after prosthetic valve replacement
Insights
High-dose Dipyridamole and Aspirin therapy significantly reduced thrombo-embolism after prosthetic valve replacement. This combination therapy proved more effective than standard care in preventing blood clots in heart valve patients.
Area of Science:
- Cardiology
- Pharmacology
- Medical Devices
Background:
- Thrombo-embolism is a significant risk following prosthetic valve replacement.
- Existing anticoagulant therapies may have limitations or side effects.
Purpose of the Study:
- To evaluate the efficacy of high-dose Dipyridamole and Aspirin in preventing thrombo-embolism after prosthetic valve replacement.
- To compare the incidence of thrombo-embolism in patients receiving this combination therapy versus a control group.
Main Methods:
- A prospective study involving 91 patients undergoing prosthetic valve replacement treated with Dipyridamole (450 mg/day) and Aspirin (3,000 mg/day) for 1 year and 2 months.
- A control group of 89 patients with prosthetic valves received standard care.
- Incidence of thrombo-embolism was assessed in both groups, stratified by time since valve replacement (less than or more than 5 years).
Main Results:
- The treated group showed a significantly lower incidence of thrombo-embolism: 1.9% (more than 5 years post-replacement) and 2.9% (less than 5 years post-replacement).
- The control group had a higher incidence: 9.1% (more than 5 years) and 14.7% (less than 5 years).
- The observed reduction in thrombo-embolism was statistically significant across both time intervals.
Conclusions:
- High-dose Dipyridamole and Aspirin therapy is an effective strategy for preventing thrombo-embolism in patients with prosthetic heart valves.
- This combination therapy offers a significant improvement in safety outcomes compared to standard care for prosthetic valve recipients.
- Further research may explore long-term outcomes and optimal dosing for this therapeutic approach.
Abstract:
In order to prevent thrombo-embolism after prosthetic valve replacement, a high dose therapy with 450 mg/day of Dipyridamole and 3,000 mg/day of Aspirin was carried out for 1 year and 2 months in 91 cases (26 cases with aortic valve replacement, 40 cases with mitral valve replacement and 25 cases with multiple valve replacement). In the treated group, the incidence was 1.9% in cases more than 5 years after valve replacement and 2.9% in cases less than 5 years after valve replacement. In contrast, in the control group of 89 cases (47 cases of aortic valve replacement, 30 cases of mitral valve replacement and 12 cases of multiple valve replacement), the incidence was 9.1% and 14.7%, respectively. Thus, in both time intervals following prosthetic valve replacement the incidence of thrombo-embolism in the treated group was significantly lower than in the control group.